Clene announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the offering. Canaccord Genuity is acting as the sole bookrunner in the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLNN:
- Clene Announces Pricing of $40 Million Public Offering
- Clene Announces Launch of Proposed Public Offering
- Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
- Clene to Participate in the Maxim Group Virtual Healthcare Conference
- Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights
